Thaden

Quick links to important sections

Thaden

Method of action: Psychoanaleptics

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Thaden

Quick Facts

Property Description
Active ingredient Dosulepin hydrochloride
Form Coated tablet or capsule
Pharmacological class Tricyclic Antidepressant (TCA)
Common use Mood regulation and support for severe psychological distress
Origin Synthetic organic compound

What is Thaden?

What Type of Medicine is Thaden (Dosulepin)?

Thaden is a prescription-only pharmaceutical preparation primarily classified as a Tricyclic Antidepressant (TCA), belonging to an established class of mood-modulating medicines. Its active component is dosulepin hydrochloride, known by the International Nonproprietary Name (INN) dosulepin. The compound is classified under the ATC code N06AA16 as an antidepressant. Thaden is one of several commercial names, like Prothiaden, associated with dosulepin, and it is clinically recognized for its use in patients requiring substantial psychotropic intervention. The medicine is supplied for oral administration, typically manufactured as a coated tablet or capsule.

Dosulepin: Composition and Nature

The composition of Thaden is based on its single-ingredient active substance, dosulepin hydrochloride. This compound is a synthetic organic molecule, structurally classified as a dibenzothiepine derivative, which is distinct from the molecular structures of more recent antidepressant medications. Its unique structure contributes to both monoamine reuptake inhibition and pronounced sedative effects. This confirms the core action focuses on regulating neurotransmitter levels in the brain. In the final pharmaceutical preparation, the active substance is contained within a solid oral matrix, alongside inactive excipients, designed for patient ingestion.

General Purpose and Function of Thaden

The general purpose of Thaden is to assist in the management of severe mood disturbances by directly influencing neurochemical signaling in the brain. It achieves this by acting as a Non-selective monoamine reuptake inhibitor, which means it increases the availability of the critical neurotransmitters serotonin and norepinephrine at nerve terminals. This rebalancing of chemical messengers provides the fundamental support needed for emotional regulation and improved psychological well-being. Furthermore, the drug’s profile includes inherent central sedative properties, which are often utilized when the patient's condition is compounded by significant anxiety or disturbed sleep patterns.

What side effects are possible with Thaden?

The official safety documentation for Thaden (dosulepin) organizes possible effects by frequency and body system, highlighting specific serious risks and population-based constraints. The primary safety concern is the medicine's low margin of safety in overdose, which is associated with high mortality due to rapid onset of severe toxicity.

Frequency-Classified Adverse Reactions

Common effects documented in regulatory labeling include anticholinergic symptoms such as dry mouth, blurred vision, constipation, and difficulty passing urine. Central nervous system effects such as drowsiness and sedation are also classified as common, often occurring early in treatment.

Rare adverse reactions include serious effects on the Blood and Lymphatic System such as bone marrow depression, thrombocytopenia, and agranulocytosis, as well as convulsions and liver problems like cholestatic jaundice.

Serious Adverse Reactions and Safety Constraints

The label lists severe Cardiovascular Toxicity as a major safety risk, encompassing serious cardiac arrhythmias, conduction defects, and circulatory collapse. This risk is present even at therapeutic doses in patients with pre-existing heart disease. Use is contraindicated following recent myocardial infarction or in the presence of any degree of heart block. Additionally, Suicidal Ideation and Behaviour are risks noted to persist until significant clinical remission and have also been reported after treatment discontinuation.

Safety is considered specifically for Older Adults, who face an increased susceptibility to cardiac toxicity, confusion, and low blood sodium (hyponatraemia). The medicine is not recommended for use in children and adolescents.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents classify Dosulepin overdose as carrying a high mortality risk due to a narrow margin of safety between therapeutic and potentially fatal doses. The onset of life-threatening toxicity is documented to occur rapidly, within four to six hours post-ingestion, which necessitates immediate intervention.

Patients must seek IMMEDIATE MEDICAL ATTENTION in all suspected cases of overdose. All children who have ingested any amount of the drug must be assessed by a physician.

Category Documented Regulatory Statements
Primary Manifestations Severe manifestations affect the Cardiovascular System (e.g., cardiac arrhythmias, severe hypotension, circulatory collapse) and the Central Nervous System (e.g., convulsions, profound loss of consciousness or coma, excitement).
Antidote Status No specific antidote is known or documented for Dosulepin overdose.
Supportive Measures Management is symptomatic and supportive. Officially described procedures include gastric decontamination and the use of intravenous benzodiazepines (e.g., diazepam, lorazepam) to control convulsions.
Monitoring Required Continuous ECG monitoring is required for a minimum of six hours post-ingestion, focusing on identifying and treating cardiac conduction defects and arrhythmias.
Population Risk Regulatory sources highlight an increased risk of cardiovascular toxicity, particularly in the elderly and in patients with severe renal disease, contributing to the severity of the overdose profile.

This profile defines the overdose situation as a medical emergency requiring rapid professional intervention due to the high likelihood of severe, systemic instability.

Therapeutic Uses of Thaden

What Thaden Treats: Main Uses and Benefits

Thaden (Dosulepin) is primarily used for managing major depressive disorder in situations where patients experience pronounced or persistent symptoms. It is applied when previous symptomatic support has been insufficient, and is commonly considered relevant in clinical settings that involve acute or unstable symptom patterns. This medication helps address the groups of symptoms that include pervasive low mood, persistent sadness, and feelings of hopelessness.

The medication's role is relevant for easing associated distress, specifically for significant psychological distress, associated anxiety, and sleep disturbances (insomnia). It also assists with maintaining functional stability during symptomatic periods by helping to ease discomfort linked to conditions presenting with systemic or localized discomfort, including symptoms of neuropathic pain. The medication supports general well-being during symptomatic phases and difficult episodes.

“It is applied across domains where additional symptomatic support is needed, contributing to easing the overall symptom load.”

Quick Fact: Supportive Symptom Focus

Property Description
Therapeutic Focus Depressive illness, complicated by anxiety and pronounced sleep disruption
Symptom Management Mood, psychological distress, and certain chronic pain manifestations
Primary Benefit Provides support that helps ease the overall symptom burden

Eligibility and Restrictions for Use

Who can and cannot use Thaden?

This medication is not suitable for everyone. Official government regulatory documents establish mandatory contraindications (absolute exclusions) and specific population restrictions.


Populations that MUST NOT use Thaden (Contraindicated):

Category Exclusion Condition
Allergy Known hypersensitivity to dosulepin or any of the product's inactive components.
Cardiac A recent myocardial infarction or existing heart block of any degree or other cardiac arrhythmias.
Neurological A current manic state.
Hepatic Severe liver disease (hepatic failure).
Concomitant Use Concurrent use with a Monoamine Oxidase Inhibitor (MAOI), or within 14 days of stopping MAOI treatment.
Age Children 12 years of age and under.

Restricted and Age-Related Eligibility:

  • Adolescents (13–18 years): Use is not recommended for the treatment of depression unless under specialist supervision.
  • Elderly Patients: Caution is required, particularly with impaired cardiovascular, renal, or hepatic function.
  • Pregnancy: Use is generally not recommended and should only be considered if deemed essential by a healthcare provider. The safety of the drug during pregnancy has not been adequately established.

These restrictions and contraindications, documented in official government labeling (such as EMA and TGA), strictly define the population for whom the medicine is considered ineligible due to the potential for serious adverse events.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Thaden (Dosulepin) is a Tricyclic Antidepressant whose interaction profile is strictly defined in regulatory documents based on two principal risks: pharmacokinetic modification and pharmacodynamic reinforcement.

Formally Contraindicated Combinations

The co-administration of Thaden with certain other medicines is formally prohibited due to the risk of severe adverse events.

  • Monoamine Oxidase Inhibitors (MAOIs): Use is contraindicated. A 14-day period without MAOIs must elapse before Thaden administration.
  • QT-Prolonging Agents: Co-administration with drugs that prolong the QT interval (e.g., Quinidine, Pimozide) is advised to be avoided due to the heightened risk of ventricular arrhythmias.

Exposure and Clearance Modification

Interactions documented in regulatory labeling can alter the concentration of Thaden in the body:

  • Increased Exposure: Medicines such as Cimetidine, Methylphenidate, and Oral Contraceptives may reduce the metabolism of Thaden, leading to increased plasma levels.
  • Reduced Exposure: Enzyme Inducers (e.g., Barbiturates, Rifampicin) may increase metabolism, potentially resulting in lowered plasma concentrations.

Pharmacodynamic and Systemic Effects

  • CNS Reinforcement: The depressant effects of alcohol and other CNS depressants (e.g., Narcotic Analgesics) are potentiated.
  • Blood Pressure: Thaden may reduce the hypotensive effect of certain antihypertensive drugs. Co-administration with Diuretics may increase the risk of postural hypotension.
  • Population Note: The elderly are cited in labeling as particularly susceptible to interaction-related adverse effects such as confusion and postural hypotension.

Mechanism of Action

Thaden's mechanism is defined by a dual-action profile, engaging both delayed neurotransmitter modulation and immediate receptor blockade, which influences its overall physiological effect.


Modulating Serotonin and Norepinephrine Transporters

This core domain involves the inhibition of reuptake transporters for serotonin (SERT) and norepinephrine (NET). This molecular action causes a rapid increase of these key transmitters in the synaptic cleft, but the resulting physiological change—the long-term functional alteration of central neurocircuits—is a gradual process that requires time-dependent neuroplastic adaptation.


Immediate Inhibition via Histamine Receptor Blockade

A mechanistic domain defined by its speed of receptor interaction involves the high-affinity antagonism of the central Histamine H1 receptors and, to a lesser extent, alpha1-adrenergic receptors. This molecular interference suppresses histaminergic neurotransmission, a system involved in regulating CNS wakefulness, leading to an inhibitory effect on central nervous system activity.


Polypharmacology and Off-Target Action

This domain addresses the drug's non-selective binding to multiple receptor systems, including the Muscarinic Acetylcholine (mAChR) receptors and Voltage-Gated Sodium Channels (VGSC). This broad activity pattern contributes to physiological adjustments in autonomic tone and nerve impulse conduction, defining the complete spectrum of physiological consequences associated with the molecule's polypharmacology.

Dosage and Administration Information

How to Use Thaden: Official Administration Guidelines

Thaden (Dosulepin) is administered solely by the oral route using the approved coated tablets or capsules. Standardized protocols outline a dosing protocol, noting that initiation of treatment for patients who have not previously received the medicine is typically restricted to specialist care providers due to the required close supervision.

Standard Dosing and Frequency

The standard adult initial dose is 75 mg daily. This dose may be taken in divided doses or as a single dose at night. The dose may subsequently be increased to a maintenance range of 75 mg to 150 mg daily. In certain circumstances, such as in-patient hospital use, dosages up to 225 mg daily have been used.

Any dose adjustment should be gradual, using increments of 25 mg to 50 mg at intervals of one to two weeks, as the full therapeutic response may take several weeks to become apparent. Following a satisfactory response, the official instruction is to reduce the dosage to the smallest amount necessary to maintain therapeutic benefit.

Population-Specific Rules

Specific dosing guidelines exist for sensitive populations. Older adults typically begin treatment with a lower dose of 50 mg to 75 mg daily, with caution advised during any increase, as half the normal adult maintenance dose is often sufficient. The medication is not routinely recommended for children, and its use in adolescents requires supervision from a specialist.

Recent Clinical Evidence

Research evidence / Overview of Studies for Thaden (Dosulepin)


Evidence for Use in Major Depressive Disorder (MDD)

Research has primarily evaluated Thaden in the context of Major Depressive Disorder (MDD) in adults. The core evidence comes from short-term Randomized Controlled Trials (RCTs). These studies research examined how symptoms change over time when compared to a placebo or another active treatment. Researchers used standardized clinical scales to measure symptom intensity or variability during the acute treatment phase, which typically lasted 6 to 12 weeks.

Studies also explored this medicine in specific populations, notably adults whose depression was not observed to respond adequately to previous treatment with newer types of antidepressants, such as SSRIs. Findings describe patterns observed in the studies over the short follow-up periods, highlighting changes measured during the study period in terms of overall depression scores and the proportion of participants who reached pre-defined score reduction criteria.

Evidence for Associated Symptoms Studied in Trials

Research for Thaden has also explored outcomes reflecting daily functioning or activity level in patients studied for depression. These studies were primarily applied in research exploring short-term symptom changes related to anxiety and sleep.

Research on Anxiety Symptoms

Anxiety was studied for how symptoms change by performing secondary analyses of the main depression trials. These studies examined standardized anxiety scale scores and overall measures of psychological distress. Findings describe group patterns that were observed in the studied populations during the acute treatment window.

Research on Sleep Disturbances (Insomnia)

Sleep disturbances, or insomnia, was also evaluated in the context of conditions characterized by fluctuating or episodic manifestations like depression. Research examined specific items on clinical rating scales that track sleep maintenance, quality, and difficulty falling asleep. Data show patterns related to changes in these sleep-related metrics was observed in some studies during the acute phase of treatment.


Evidence for Use in Chronic Neuropathic Pain

Thaden was studied for certain types of chronic pain syndromes that involve outcomes related to physical discomfort. Research includes specific RCTs that was evaluated in the context of conditions such as psychogenic facial pain and specific types of persistent nerve pain. The evidence base here contributes to understanding symptom patterns where these outcomes was observed in some studies during the defined time intervals.

Key Limitations and Areas of Research Uncertainty

Key limitations include that follow-up durations were limited in many pivotal trials, meaning long-term effects are not fully established. Also, results apply only to the populations studied (e.g., non-psychotic MDD), which means data for certain groups remain insufficient, and the evidence quality varies across studies for secondary indications like anxiety or sleep disturbances. Overall, comparative evidence is lacking in some areas, and much of the data reflects research exploring short-term symptom changes rather than sustained, long-term outcomes.

Key Studies & References Health Products Regulatory Authority (HPRA) Public Assessment Report for Dosulepin Hydrochloride Azure 75 mg Tablet (Regulatory Document)

Frequently Asked Questions (FAQ)

Common questions about Thaden (FAQ)

Q: Is Thaden similar to other common medicines for the same condition?

Thaden contains dosulepin, which belongs to an older class of medication known as Tricyclic Antidepressants (TCAs). Official guidance in various regions often describes this medicine as being typically used when a person has not responded well to, or cannot tolerate, newer types of antidepressants. This classification indicates its molecular structure and action profile are distinct from that of commonly prescribed SSRIs.

Q: How quickly does Thaden usually start to have an effect?

According to official product information, patients should generally expect to wait two to four weeks of treatment before improvements in mood become noticeable. However, some people may start to observe an earlier improvement in anxiety symptoms associated with their condition. The full therapeutic benefit is generally noted to be a gradual process requiring time.

Q: Do you need to take Thaden for a long time?

The duration of use depends on the condition being managed. For a first episode of depression, official guidance suggests continuing treatment for about six months after symptoms have improved. For individuals who have experienced two or more episodes, long-term use (often cited as one to five years or longer) has been examined in studies for maintaining therapeutic benefit and reducing recurrence.

Q: What should someone expect the first few days of using Thaden?

In the first few days of use, common effects described in official documents include drowsiness, sedation, dry mouth, and blurred vision. These central nervous system effects are usually most pronounced at the start of treatment. Product information often notes that drowsiness and sedation frequently lessen as the body adjusts to the medicine.

Q: Does Thaden cause any long-term health concerns?

Studies examining the very long-term effects of Thaden have limited follow-up durations, meaning its effects over many years are not fully established in research. However, the documented safety profile includes risks of bone fractures and potential cardiac toxicity that are noted as considerations, particularly for older adults or those with pre-existing heart conditions.

Q: What does it mean that Thaden is 'metabolized' by the liver?

When a medicine is metabolized, it means the body is breaking it down, primarily through enzymes in the liver. Regulatory documents discuss this process because certain other medicines can interfere with the liver's function. This interference can either speed up or slow down the breakdown of Thaden, which may change the amount of medicine circulating in the body.

Q: Why do official documents mention 'unknown risk' with Thaden for some populations?

Official documents use cautionary language like 'unknown risk' to indicate groups where the medicine's safety and effectiveness have not been sufficiently studied. This is particularly noted in populations such as children or during pregnancy, where there is a lack of adequate data. This language reflects the principle that caution is applied in populations where there is insufficient evidence to rule out potential side effects.

Q: What are the official warnings about stopping Thaden suddenly?

The official product information includes warnings that abrupt discontinuation (stopping suddenly) may lead to various withdrawal symptoms. These symptoms can include insomnia, headache, anxiety, and increased sweating. For this reason, regulatory documents describe that the dose is typically reduced gradually over several weeks rather than stopped all at once.

Q: What kind of common over-the-counter pain relievers can interact with Thaden?

Official guidance on drug interactions notes a potential concern when Thaden is combined with common Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen. This combination is associated with an increased risk of gastrointestinal bleeding. Official documents also mention that NSAIDs may increase the risk of developing low sodium levels (hyponatraemia) when used with Thaden.

Q: Is it necessary to take Thaden with food?

Official patient information states that Thaden tablets or capsules should be swallowed whole with a drink of water. It is noted that the medicine can be taken with or without food. Specific guidance regarding food intake is determined by the prescribing healthcare provider.

Q: Does Thaden interact with vitamins or herbal supplements?

Official product warnings advise that this medicine has the potential to interact with a large number of other products. For this reason, official product information highlights the importance of discussing the use of all other substances with a healthcare provider, including any vitamins, dietary supplements, or herbal remedies they may be taking.

Q: If I miss a dose of Thaden, what is the official guidance?

Official patient information notes that if a dose is missed, a person is generally directed not to take a double dose to make up for it. Instead, they should simply resume the regular dosing schedule by taking the next dose at the usual time. Some instructions specifically caution against taking a large missed dose too late in the evening.

Q: Is there a generic version of Thaden available?

Yes, the active ingredient in Thaden is Dosulepin Hydrochloride. This compound is commonly available under its generic name (dosulepin) as well as under several different brand names worldwide. Therefore, generic formulations of the medicine are widely accessible.

Q: Is it okay to drive while taking Thaden?

Official regulatory guidance addresses caution regarding driving and operating machinery. Because the medicine can cause drowsiness, dizziness, and blurred vision, official documentation describes that activities requiring alertness, such as driving or operating machinery, are generally avoided until an individual knows how the medicine affects them.

Q: What happens if I forget to take Thaden for several days?

The official patient information focuses on guidance for a single missed dose and does not specify what to do after forgetting the medicine for several consecutive days. However, any sudden, unplanned interruption of treatment carries the risk of experiencing the withdrawal symptoms mentioned in the safety warnings.

Q: Does Thaden require any special monitoring or lab tests while using it?

Official regulatory warnings advise that patients with certain pre-existing conditions may require regular medical monitoring while using this medicine. This is particularly noted for individuals with a history of seizures, heart conditions, or impaired liver or kidney function. Specific lab tests or procedures are determined by the prescribing doctor based on individual health factors.

Q: Can Thaden cause weight loss or increase appetite?

Regulatory documents cite increased appetite and resulting weight gain as common side effects associated with this medication. Conversely, some official product information documents also note weight loss as a possible, though less frequent, outcome.

How should Thaden be stored and disposed of?

How to Store and Dispose of Thaden?

The storage and disposal of Thaden (dosulepin) must strictly follow official regulatory guidelines to maintain its stability and ensure safety.

Requirement Category Official Regulatory Statement
Storage Temperature Store at or below 25 C for capsules, or below 30 C for tablets, depending on the label.
Protection and Container Keep the medicine in its original container and protected from light and moisture.
Child-Safety Rule Must be stored out of the sight and reach of children due to high toxicity risk.
Disposal Instructions Do not dispose of in wastewater or household trash. Return unused or expired product to a drug take-back program or pharmacist, or follow the FDA’s trash disposal steps if no program is available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Thaden found in:

A-Z Index: